Ohtuvayre (ensifentrine)
Research Synopsis
- * Research indicates that ensifentrine demonstrates significant bronchodilation and anti-inflammatory effects, potentially offering new treatment options for patients who do not respond well to existing therapies.
- * Clinical studies have shown that ensifentrine can improve lung function significantly in COPD patients, with enhancements in peak forced expiratory volume (FEV1) observed during trials.
- * Various studies highlight ensifentrine's ability to reduce respiratory symptoms and improve quality of life, with a dose-dependent response resulting in notable reductions in breathlessness.
- * Ensifentrine has displayed synergistic effects when used alongside other medications, like glycopyrronium and tiotropium, enhancing overall bronchodilation and therapeutic outcomes.
- * The drug has been evaluated in diverse study populations, including healthy participants and those with moderate to severe chronic respiratory conditions, demonstrating its robust safety profile and tolerability.
- * Preliminary investigations suggest potential in treating cystic fibrosis (CF) by enhancing CFTR activity and promoting mucus clearance, although further research is needed.
- * Ensifentrine's dual action targets both breathing difficulties and inflammation, suggesting it may serve as a comprehensive treatment approach for various airway diseases.
- * Comparisons in studies with traditional bronchodilators, like salbutamol, indicate that ensifentrine could potentially outperform existing options in terms of both efficacy and safety.
- * Overall, ensifentrine's innovative mechanism of action and favorable clinical outcomes position it as a promising addition to therapeutic strategies for respiratory diseases.
Ohtuvayre (ensifentrine)
The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]is
London, UK
2 hours ago
1 Received
- - The study investigates the pharmacological effects of two novel PDE3/4 inhibitors, RPL554 and RPL565, which demonstrate significant inhibition of contractions in guinea pig tracheal preparations, indicating potential for respiratory applications.
- - Both compounds effectively suppress the release of inflammatory markers from human monocytes and reduce cell proliferation, showcasing their anti-inflammatory properties in various in vitro assays.
- - In vivo tests reveal that RPL554 and RPL565 substantially inhibit eosinophil recruitment and inflammation responses in guinea pigs, suggesting their promise as long-acting treatments for respiratory conditions.
$100 - $150
Hourly Rate
The COPD Pipeline XIV.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
The COPD pipeline XX.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone.
London, UK
2 hours ago
1 Received
- - The study focuses on the effects of RPL554, a dual inhibitor of PDE3 and PDE4 enzymes, on airway smooth muscle (ASM) relaxation and its interaction with muscarinic receptor antagonists and a β2-agonist.
- - RPL554 was found to significantly inhibit contractions induced by electrical stimulation, acetylcholine, and histamine in isolated human bronchi, demonstrating high effectiveness in promoting muscle relaxation.
- - Notable synergistic interactions were observed between RPL554 and atropine or glycopyrrolate, suggesting that RPL554 could offer a promising treatment for airway diseases when used alone or in combination with other drugs.
$100 - $150
Hourly Rate
Dual PDE 3/4 inhibition: a novel approach to airway disease?
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
London, UK
2 hours ago
1 Received
- Researchers evaluated a new inhaled drug, RPL554, which combines phosphodiesterase 3 and 4 inhibition, to see if it could improve treatment for patients with severe asthma or COPD who don't respond well to existing medications.
- The study consisted of four clinical trials conducted in the Netherlands, Italy, and the UK between 2009 and 2013, involving healthy participants and those with mild asthma or COPD, to assess RPL554’s safety, effectiveness in bronchodilation, and anti-inflammatory properties.
- Results showed RPL554 potentially provides bronchodilation and reduces inflammation, indicating it could be a promising treatment option for patients with severe respiratory conditions.
$100 - $150
Hourly Rate
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways.
London, UK
2 hours ago
1 Received
- RPL 554, a dual PDE3/4 inhibitor, enhances bronchodilation when used with glycopyrronium, particularly for patients with asthma and COPD.
- In experiments with isolated human bronchi, both drugs showed significant relaxation effects, especially when combined, extending the duration of relief.
- This study suggests that using RPL554 and glycopyrronium together may provide greater benefits for patients suffering from respiratory conditions like asthma and COPD due to their synergistic effects.
$100 - $150
Hourly Rate
The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia.
London, UK
2 hours ago
1 Received
- Cystic fibrosis (CF) is a genetic disorder caused by CFTR gene mutations, leading to chronic infections and inflammation in the airways.
- Research shows that phosphodiesterase (PDE) inhibitors, like RPL554, can enhance CFTR activity by increasing intracellular cAMP levels, which could benefit CF patients.
- RPL554 not only boosts CFTR-dependent ion secretion in specific CF genotypes but also improves cilia movement, suggesting it might improve mucus clearance and serve as a new treatment option for CF.
$100 - $150
Hourly Rate
Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility.
London, UK
2 hours ago
1 Received
- The study investigated the effectiveness of RPL554, a dual PDE3 and PDE4 inhibitor, in relaxing airway smooth muscle compared to other bronchodilators like salbutamol and ipratropium bromide.
- The experimental setup involved testing various drugs on guinea pig tracheal preparations to measure their relaxation effects under controlled conditions.
- Results showed that RPL554 achieved nearly maximum relaxation across different spasmogenic agents and outperformed salbutamol when used with muscarinic antagonists, indicating its potential for better bronchodilation in patients with constricted airways.*
$100 - $150
Hourly Rate
An inhaled "bifunctional" dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD.
London, UK
2 hours ago
1 Received
- The study investigated the short-term effects of RPL554, a dual phosphodiesterase inhibitor, when used with other bronchodilators in patients with chronic obstructive pulmonary disease (COPD) who showed reversibility to short-acting bronchodilators.
- Two main studies were conducted: one was a six-way crossover trial comparing RPL554 with salbutamol and ipratropium, while the other was a three-way study examining RPL554 with tiotropium.
- Results indicated that combining RPL554 with standard bronchodilators significantly improved lung function, showing a greater peak forced expiratory volume (FEV) compared to monotherapy, suggesting enhanced
$100 - $150
Hourly Rate
Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.
London, UK
2 hours ago
1 Received
- Ensifentrine (RPL554) is an inhaled medication that acts as a dual phosphodiesterase 3/4 inhibitor, meaning it helps relax airways and reduce inflammation.
- It is currently being investigated as a treatment option for chronic obstructive pulmonary disease (COPD) and other inflammatory airway conditions.
- The specific role of Ensifentrine in COPD management is still uncertain, as it may serve as either an add-on treatment during acute flare-ups or as a regular maintenance therapy, possibly alongside other medications.
$100 - $150
Hourly Rate
Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma.
London, UK
2 hours ago
1 Received
- This study investigated the effects of nebulised ensifentrine, a dual phosphodiesterase inhibitor, on asthma patients by comparing different doses to a placebo and salbutamol.
- It was a double-blind, randomized, and controlled trial with 29 participants, focusing on lung function improvement and safety measures over a 12-hour period.
- Results showed that ensifentrine had a clear dose-response in improving lung function, was well tolerated, and did not cause the typical side effects associated with other asthma treatments like salbutamol.
$100 - $150
Hourly Rate
Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD.
London, UK
2 hours ago
1 Received
- A compound that inhibits both PDE3 and PDE4, like Ensifentrine, may improve airway function by relaxing muscles and reducing inflammation in conditions like asthma and COPD.
- Ensifentrine is currently being studied in Phase II trials, but its role in treating COPD and asthma is still unclear due to insufficient research.
- While there's potential for Ensifentrine in cystic fibrosis treatment, more rigorous studies are needed to understand its anti-inflammatory effects and solidify its therapeutic use.
$100 - $150
Hourly Rate
A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD.
London, UK
2 hours ago
1 Received
- * The study included 405 patients, randomized to receive different doses of ensifentrine or a placebo, with a primary focus on changes in peak forced expiratory volume (FEV) after four weeks.
- * Results showed that all doses of ensifentrine significantly improved FEV compared to placebo and reduced respiratory symptoms, although some patients reported adverse events.
$100 - $150
Hourly Rate
The dual phosphodiesterase 3/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants.
London, UK
2 hours ago
1 Received
- * The study investigates the effects of the dual phosphodiesterase (PDE) inhibitor RPL554 on various rare CFTR mutants, showing it can increase cAMP levels and enhance CFTR function in lab models and human airway cells.
- * Findings suggest that RPL554 has therapeutic potential for cystic fibrosis patients with specific class III and IV CFTR mutations, and support PDEs as promising drug targets for treatment.
$100 - $150
Hourly Rate
The Phosphodiesterase Inhibitor Ensifentrine Reduces Production of Proinflammatory Mediators in Well Differentiated Bronchial Epithelial Cells by Inhibiting PDE4.
London, UK
2 hours ago
1 Received
- Cystic fibrosis (CF) is caused by mutations in the CFTR channel, leading to issues with airflow and chronic lung inflammation due to excessive proinflammatory cytokines during infections.
- The PDE inhibitor ensifentrine has been shown to improve CFTR function and reduce the production of inflammatory cytokines in CF bronchial cells, primarily through the inhibition of PDE4.
- Combining ensifentrine with a beta-adrenergic agonist or corticosteroid enhances its anti-inflammatory effects, suggesting it could be a promising treatment strategy for managing inflammation in CF airways.
$100 - $150
Hourly Rate
Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis.
London, UK
2 hours ago
1 Received
- Ensifentrine is an innovative inhaled treatment that targets dual phosphodiesterase (PDE) 3 and 4, showing significant improvements in respiratory symptoms for COPD patients during a four-week clinical trial.
- The study involved COPD patients aged 40-75, measuring improvements in respiratory symptoms using multiple standardized questionnaires over the trial period, with results indicating all doses of ensifentrine performed better than a placebo.
- The findings highlight that patients experienced notable early improvements in breathlessness and overall respiratory symptoms, particularly at higher doses of ensifentrine compared to placebo.
$100 - $150
Hourly Rate
A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy.
London, UK
2 hours ago
1 Received
- Ensifentrine is an inhaled medication that inhibits enzymes linked to inflammation and has been found to improve lung function in COPD patients when used alongside tiotropium over a 4-week period.
- A clinical study involved 416 patients with moderate-to-severe COPD, showing that ensifentrine significantly enhanced lung function, measured by peak forced expiratory volume (FEV1), in a dose-dependent manner compared to placebo.
- The study also observed meaningful improvements in health-related quality of life, as measured by the St. George's Respiratory Questionnaire, with no notable difference in adverse events between the ensifentrine and placebo groups.
$100 - $150
Hourly Rate
Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosis.
London, UK
2 hours ago
1 Received
- Cystic Fibrosis (CF) lung disease is caused by mutations in the CFTR protein, which lead to reduced anion and fluid secretion in the airways, compromising lung defense and causing bacterial infections and tissue damage.
- Restoration of CFTR function is a key target for CF treatments, often through the activation of CFTR by cyclic nucleotide-dependent pathways.
- The study focuses on phosphodiesterase (PDE) enzymes that regulate these pathways, exploring how PDE inhibitors can increase cyclic nucleotide levels and thus potentially improve CFTR function, mucociliary transport, inflammation control, and bronchodilation in CF patients.
$100 - $150
Hourly Rate